Page 3 - Biontech Se News Today

A vaccine based on messenger RNA (mRNA) technology against four surface proteins of the envelope and the inner membrane of the mpox virus (MPXV) demonstrated its efficacy in two animal models. Biontech SE scientists designed and tested two different combinations of antigens in mice and macaques for the two infective forms of the virus. One of them showed better results for its evaluation in clinical trials preventing the disease.

NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE...

By Najat Kantouar BioNTech said that it has agreed to invest $200 million in Autolus Therapeutics, starting a strategic collaboration to advance its pipeline...

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE...

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE...

If you suffered losses exceeding $100,000 investing in BioNTech stock or options between March 30, 2022 and October 13, 2023 and would like to discuss your...

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE...

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

By Josh Beckerman BioNTech shares were down 3.4% after the company projected 2024 revenue of about 3 billion euros ($3.28 billion), compared with the average...

This year’s rollout marks a definitive transition to a commercial market for the vaccines, which had previously been purchased by the U.S. government....